PlasmaGen Biosciences, a pioneering Indian biopharmaceutical firm focused exclusively on plasma-derived therapeutics, has closed a ₹150 crore minority equity financing round at a valuation exceeding ₹1,500 crore. The round was led by specialty biopharma company ViNS Bioproducts, with participation from high-net-worth individuals (HNIs), family offices, pharmaceutical entrepreneurs, and existing investors including Eight Roads Ventures.

This fresh capital injection bringing the company’s total funding to over ₹600 crore since inception will primarily fuel international expansion, including identified distribution partnerships in key export markets and ongoing regulatory approvals to commence global sales. Domestically, PlasmaGen continues to strengthen its footprint through a cold-chain-backed network serving private hospitals and state governments with essential plasma products.

The company has seen transformative momentum since 2024, when it commenced commercial operations at its state-of-the-art plasma fractionation facility in Kolar, Bengaluru the first such pure-play facility in India and only the fifth overall. This advanced infrastructure has enabled rapid revenue growth and positioned PlasmaGen to address critical unmet needs in areas like immunodeficiency, bleeding disorders, and other plasma protein deficiencies.

To support its next growth phase, PlasmaGen has bolstered its leadership with key appointments: Vivek V Kamath as CEO, Sethu Madhavan as COO (manufacturing and technical operations), and Arnav Jain as CFO.

The funding underscores strong investor confidence in PlasmaGen’s operating model, world-class manufacturing, and long-term potential as a differentiated player in the global plasma biopharmaceutical space.